Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

42 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prognostic impact of adjuvant endocrine therapy for estrogen receptor-positive and HER2-negative T1a/bN0M0 breast cancer.
Sasada S, Kondo N, Hashimoto H, Takahashi Y, Terata K, Kida K, Sagara Y, Ueno T, Anan K, Suto A, Kanbayashi C, Takahashi M, Nakamura R, Ishiba T, Tsuneizumi M, Nishimura S, Naito Y, Hara F, Shien T, Iwata H. Sasada S, et al. Among authors: kanbayashi c. Breast Cancer Res Treat. 2023 Dec;202(3):473-483. doi: 10.1007/s10549-023-07097-6. Epub 2023 Sep 9. Breast Cancer Res Treat. 2023. PMID: 37688665 Free PMC article.
[Launch of the Japan Association of Women Surgeons].
Kawase K, Yorozuya K, Tomizawa Y, Nomura S, Akashi S, Kanbayashi C, Kawamoto S, Takamatsu H, Nagata Y, Teramoto T. Kawase K, et al. Among authors: kanbayashi c. Nihon Geka Gakkai Zasshi. 2010 May;111(3):180-1. Nihon Geka Gakkai Zasshi. 2010. PMID: 20540334 Japanese. No abstract available.
Treatment outcomes and prognostic factors for patients with brain metastases from breast cancer of each subtype: a multicenter retrospective analysis.
Niikura N, Hayashi N, Masuda N, Takashima S, Nakamura R, Watanabe K, Kanbayashi C, Ishida M, Hozumi Y, Tsuneizumi M, Kondo N, Naito Y, Honda Y, Matsui A, Fujisawa T, Oshitanai R, Yasojima H, Tokuda Y, Saji S, Iwata H. Niikura N, et al. Among authors: kanbayashi c. Breast Cancer Res Treat. 2014 Aug;147(1):103-12. doi: 10.1007/s10549-014-3090-8. Epub 2014 Aug 9. Breast Cancer Res Treat. 2014. PMID: 25106661
Prognostic factors of HER2-positive breast cancer patients who develop brain metastasis: a multicenter retrospective analysis.
Hayashi N, Niikura N, Masuda N, Takashima S, Nakamura R, Watanabe K, Kanbayashi C, Ishida M, Hozumi Y, Tsuneizumi M, Kondo N, Naito Y, Honda Y, Matsui A, Fujisawa T, Oshitanai R, Yasojima H, Yamauchi H, Saji S, Iwata H. Hayashi N, et al. Among authors: kanbayashi c. Breast Cancer Res Treat. 2015 Jan;149(1):277-84. doi: 10.1007/s10549-014-3237-7. Epub 2014 Dec 21. Breast Cancer Res Treat. 2015. PMID: 25528021
Serum lipid and bone metabolism effects of Toremifene vs. Letrozole as adjuvant therapy for postmenopausal early breast cancer patients: results of a multicenter open randomized study.
Shien T, Doihara H, Sato N, Anan K, Komaki K, Miyauchi K, Yanagita Y, Fujisawa T, Mitsuyama S, Kanbayashi C, Kusama M, Kimura M, Jinno H, Sano M, Ikeda T. Shien T, et al. Among authors: kanbayashi c. Cancer Chemother Pharmacol. 2018 Feb;81(2):269-275. doi: 10.1007/s00280-017-3491-6. Epub 2017 Dec 1. Cancer Chemother Pharmacol. 2018. PMID: 29196963 Free PMC article. Clinical Trial.
Comparison of immune microenvironments between primary tumors and brain metastases in patients with breast cancer.
Ogiya R, Niikura N, Kumaki N, Yasojima H, Iwasa T, Kanbayashi C, Oshitanai R, Tsuneizumi M, Watanabe KI, Matsui A, Fujisawa T, Saji S, Masuda N, Tokuda Y, Iwata H. Ogiya R, et al. Among authors: kanbayashi c. Oncotarget. 2017 Oct 27;8(61):103671-103681. doi: 10.18632/oncotarget.22110. eCollection 2017 Nov 28. Oncotarget. 2017. PMID: 29262592 Free PMC article.
Neoadjuvant endocrine therapy with exemestane followed by response-guided combination therapy with low-dose cyclophosphamide in postmenopausal patients with estrogen receptor-positive breast cancer: A multicenter, open-label, phase II study.
Sato N, Masuda N, Morimoto T, Ueno T, Kanbayashi C, Kaneko K, Yasojima H, Saji S, Sasano H, Morita S, Ohno S, Toi M. Sato N, et al. Among authors: kanbayashi c. Cancer Med. 2018 Jul;7(7):3044-3056. doi: 10.1002/cam4.1600. Epub 2018 Jun 14. Cancer Med. 2018. PMID: 29905023 Free PMC article.
Neoadjuvant exemestane or exemestane plus docetaxel and cyclophosphamide tailored by clinicopathological response to 12 weeks' exemestane exposure in patients with estrogen receptor-positive breast cancer: A multicenter, open-label, phase II study.
Sato N, Masuda N, Morimoto T, Ueno T, Kanbayashi C, Kaneko K, Yasojima H, Saji S, Sasano H, Morita S, Ohno S, Toi M. Sato N, et al. Among authors: kanbayashi c. Cancer Med. 2019 Sep;8(12):5468-5481. doi: 10.1002/cam4.2423. Epub 2019 Jul 30. Cancer Med. 2019. PMID: 31361400 Free PMC article. Clinical Trial.
42 results